Clinical nuclear medicine · 2017
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garcia J R, Pérez Cristina, Bassa Pere, Capdevila Laia, Ramos Francisco, Valenti Vicens
Аннотация
In hormone receptor-positive locally advanced breast cancer, endocrine therapy becomes an integral part of the therapeutic strategy. There are now significant numbers of available hormonal directed compounds, including selective aromatase and mTOR inhibitors, which allow an important therapeutic advance in these patients. Sequential F-FDG PET/CT studies provided essential information regarding response to different treatments, including targeted therapies, and adverse therapeutic effects that helped to better define the right moment to implement each therapeutic approach.
Предметные рубрики MeSH
AdultAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsAxillaBone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDiphosphonatesDocetaxelEpirubicinFemaleFluorodeoxyglucose F18FluorouracilGonadotropin-Releasing HormoneHumansImidazolesLetrozoleLymph Node ExcisionLymph NodesMastectomyMultimodal ImagingNeoadjuvant TherapyNeoplasm StagingNitrilesPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRadiotherapyRibsTaxoidsTriazolesZoledronic Acid